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Abstract
Mucormycosis is an emerging fungal infection worldwide, with devastating disease symptoms and diverse clinical manifestations. The most
important underlying risk factors are immunosuppression, poorly controlled diabetes, iron overload and major trauma. The aetiological
agents involved in the disease have been re-classiﬁed due to changes in taxonomy and nomenclature, which also led to appropriately naming
the disease ‘mucormycosis’. This article shortly explains the new nomenclature, clinical manifestations and risk factors and focuses on
putative virulence traits associated with mucormycosis, mainly in the group of diabetic ketoacidotic patients.
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Introduction
Invasive fungal infections caused by the members of Mucorales
(mucormycosis) are relatively rare but have increased in the
last years [1]. These aggressive and highly destructive infec-
tions occur predominantly in immunocompromised hosts,
especially in patients with haematological malignancies or
those receiving hematopoietic stem cell transplantation. Dia-
betic patients with ketoacidosis and patients with transfusional/
dyserythropoetic iron overload are unique risk groups. The
difﬁculties in diagnosis and subsequent antifungal treatment,
partly due to a highly intrinsic resistance to many of the
commonly used antifungal drugs [2,3], still leads to high
mortality rates in certain patient groups [4].
Compared to other fungal pathogens, such as Aspergillus
fumigatus or Candida albicans, only little is known so far on
fungal properties leading to successful infection and host
immune response to the various representatives of the
Mucorales.
The Pathogens-Taxonomic Changes and
Biological Characteristics
These pathogens display a highly diverse group, whose classi-
ﬁcation is in a constant state of ﬂux. Until more than a decade
ago, the phylum Zygomycota comprised the Mucorales, Ento-
mophtorales and eight other orders which included fungi that
were not considered to be human pathogens [5]. A compre-
hensive phylogenetic re-analysis of the kingdom Fungi, based on
molecular methods [6], resulted in elimination of the polyphy-
letic phylum Zygomycota and placing the various taxa into the
phylum Glomeromycota divided into four subphyla: Mucoro-
mycotina, Entomophthoromycotina, Kickxellales and
Zoopagomycotina (elevating the orders Mucorales and Entom-
ophthorales to a subphylum status). Various gene regions have
been used to separate lineages of the Glomeromycota, including
ribosomal RNA subunits, elongations factors, a- and b-tubulins
and mitochondrial small subunit ribosomal DNA [7–10]. This
classiﬁcation scheme might undergo further revision, but the
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Mucoromycotina and Entomophthoromycotina are clearly
separated into two different clades and are not related.
The changes in taxonomy were accompanied by a renaming
of the disease caused by these aetiologic agents. The term
‘zygomycosis’, deﬁned in 1976 by Ajello et al. [11], and
describing any invasive fungal infection caused by species of
the former phylum Zygomycota was replaced by either
‘mucormycosis’ or ‘entomophthoromycosis’ [9]. Due to the
differences in morphology, ecology, epidemiology and the
clinical pictures, the various causative agents are able to
induce, ‘mucormycosis’ or ‘entomophthoromycosis’ is clini-
cally a more speciﬁc name than ‘zygomycosis’.
The Entomophthoromycotina, natural insect pathogens
represented by the two genera Conidiobolus and Basidiobolus,
are found in tropical and subtropical regions of the world,
where they can cause chronic subcutaneous infections mostly
in otherwise healthy patients [12].
The Mucoromycotina are found worldwide as common
saprobes on decaying organic material or agricultural and
forest soils. They are fast-growing organisms, characterized by
large, ribbon-like hyphae with no or only few septae. Disease
caused by representatives of the Mucoromycotina comprises
severe and potentially life-threatening infections, particularly in
the immunocompromised patient. The genera mainly involved
in human disease (summarized in Table 1) are Cunninghamella,
Lichtheimia (formerly Absidia), Mucor, Rhizomucor, Rhizopus and,
depending on geographical distinction, Apophysomyces and
Saksenaea [9,12,13]. The clinical characteristics will be further
explained in the following chapters where we will focus on the
Mucoromycotina as they play an increasing role in the clinical
setting in the Western world.
The Infection-Clinical Manifestations
Tissue necrosis due to invasion of blood vessels and
subsequent thrombosis are the hallmarks of invasive
mucormycosis. Furthermore, infections with Mucorales are,
in most cases, characterized by rapid progression. Mortality
rates vary, depending on the site of infection and the condition
of the host. Nevertheless, rates of death are estimated to
range between 40 and 70%, even with antifungal therapy [14–
19]. The challenge associated with diagnosis of Mucormycosis
is not only a reason for high mortality rates, but also makes it
difﬁcult to determine the exact incidence of the disease.
Furthermore, studies show differences in capture periods,
populations, and deﬁnition of proven/probable cases. A recent
study carried out in France over a 10 year period, showed,
that the annual population-based incidence rate increased by
7.4% per year (from 0.7 to 1.2 cases/million persons in 2006)
[20]. The speciﬁc annual incidence rate rose by 24% per year in
patients with haematological malignancies, which increased
from 0.02 to 0.2 cases/million over time. Similar, Roden et al.
[19] reported an increase of mucormycosis in immunocom-
promised patients in the 1980s and 1990s.
Classiﬁcation of mucormycosis is performed according to
the anatomic site of infection, reﬂecting in part the portals of
entry in the human body. Spores enter the body either via the
respiratory tract, through injured skin or via the percutaneous
route (e.g. transmission of spores by contaminated needles or
catheters), or via ingestion of contaminated food. Disease may
present as rhino-orbital-cerebral, pulmonary, cutaneous/sub-
cutanous, gastrointestinal or disseminated form [21,22].
Rhino-orbital-cerebral disease deﬁnes an infection that
originates in the paranasal sinuses, following inspiration of
spores, and possible extension to the brain. Sequentially, nose,
sinuses, eyes and brain are affected. Symptoms at early stage of
disease might be sinus pain, nasal congestion, fever, soft tissue
swelling and headache. Nasal ulceration might occur as well.
Progression of disease, which usually is rapid if not treated,
results in extension to neighbouring tissues, thrombosis and
further necrosis, causing painful black eschar on the palate or
nasal mucosa. Extension to the eyes is possibly, leading to
blurred vision or even complete loss of vision. From the eyes
the disease can progress towards the central nervous system
resulting in altered consciousness, cranial neuropathies or
cerebral abscesses [22,23].
Clinical manifestations of pulmonary mucormycosis are very
similar to those of pulmonary aspergillosis [15,24]. Chest
radiographs from patients with pulmonary aspergillosis are
indistinguishable from those with pulmonary mucormycosis.
Interestingly, Camilos et al. [15,24] found independent predic-
tors for pulmonary mucormycosis in a retrospective study
reviewing clinical characteristics and CT features in 45 patients
with cancer and either pulmonary aspergillosis or pulmonary
mucormycosis. Appearance of more than ten nodules as well
as the formation of micronodules were shown to be more
TABLE 1. Classiﬁcation of clinically relevant fungi formerly
regarded as ‘zygomycetes’ [9,13]
Subphylum Genus
Species most
frequently isolated
from patients
Mucormycotina Apophysomyces A. variabilis
Cunninghamella
Lichtheimia (Absidia)
C. bertholletiae
L. corymbifera
L. ramosa
Mucor M. circinelloides
Rhizopus R. arrhizus (oryzae)
R. microsporus
Rhizomucor R. pusillus
Saksenaea S. vasiformis
Entomophthoromycotina Basidiobolus B. ranarum
Conidiobolus C. coronatus
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 6), 60–66
CMI Binder et al. Mucormycosis 61
common in patients with pulmonary mucormycosis, and
therefore regarded as signiﬁcant predictors. Involvement of
the sinuses was seen to occur only in patients who suffered
from pulmonary mucormycosis. In general, fever and cough are
the symptoms seen in most patients, together with pleuritic
chest pain and dyspnoea. In case the pathogen is invading blood
vessels, massive hemoptysis can occur, as well as a systemic
dissemination of the disease.
Cutaneous mucormycosis can develop after inoculation of
traumatic skin wounds or burns, or-in some rare cases, result
from disseminated disease [19,25–27].
If primarily acquired by direct inoculation into wounds,
acute inﬂammatory response is seen with the formation of
abscesses, skin swelling and necrosis. Characteristically, the
initially red lesions develop to black eschar. Further progres-
sion into deeper tissue effecting muscles, tendons or bone is
possible and may also lead to disseminated disease [28]. In
patients with large open wounds, lesions with areal hyphae,
visible by eye, have been observed [29].
Gastrointestinal manifestation, caused by the uptake of
contaminated food or beverages, is relatively uncommon [19].
In some cases, the use of contaminated herbal and homoeo-
pathic medicines has been linked to gastrointestinal disease
development [30,31]. The disease can affect any part of the
alimentary system, but is mostly seen in the stomach [22,32].
Symptoms depend on the location of the disease and usually
abdominal pain, distention together with nausea and vomiting
are seen.
The disseminated form of mucormycosis may originate
from any primary sites of infection. It has been reported in
pulmonary, cerebral and cutaneous disease [19]. In most cases,
the organ from which dissemination occurs is the lung, but the
disease can also spread from the alimentary tract or wounds.
Symptoms are of great variety, which make diagnosis even
harder, but a metastatic skin lesion is certainly a sign to suspect
disseminated mucormycosis.
Risk Factors
Although there have been some reports of Mucormycosis in
immunocompetent people [19,22,32], it is still regarded an
opportunistic disease and speciﬁc risk factors for mucormycosis
in different patient populations have been identiﬁed. Mostly, the
disease affects patients with haematological malignancies (HM)
and prolonged severe neutropenia. Outstanding in comparison
to other fungal infections is the high incidence amongst patients
with poorly controlled diabetes, especially complicated by
ketoacidosis (DKA), patients with iron overload or those who
underwent major trauma [19,33–35].
Highest at risk for the development of mucormycosis are
patients, who either have decreased amounts of mononuclear
and polymorphonuclear phagocytes, that would inhibit germi-
nation of spores in healthy humans, or whose underlying
disease disturbs the function of their phagocytotic cells. This
includes patients with HM, patients who underwent hemato-
poetic stem cell transplantation and also patients who received
high-dose corticosteroid treatment [36–38].
This also accounts for diabetic patients, especially those
whose disease is poorly controlled. In DKA patients, elevated
levels of free iron in serum are caused by a release of iron from
binding proteins such as transferrin, which is due to a
decreased pH level. The dysfunction of glucose and iron
metabolism, and regulation of this, was shown to result in
decreased phagocytic function and intracellular killing of
R. oryzae [39–42]. Additionally, chemotaxis of neutrophils
was shown to be impaired in murine models to whom high
amounts of iron were given, but could be prevented by
applying the iron chelator deferasirox [43].
Therapy with the iron chelator deferoxamine (DFO) further
enhances the risk for angioinvasive mucormycosis [44], the
reason for which was subsequently proven to be the ability of
DFO to act as a xenosiderophore after free iron was bound. In
contrast, other iron chelators, such as deferasirox and
deferiprone, were shown not to be used as xenosiderophores
by Rhizopus [43,45,46]. Therefore, these iron chelators do not
increase the risk for development of mucormycosis.
The breakdown of the skin-barrier and/or soft tissue
injuries, caused by local trauma or burns, is another risk
factor for mucormycosis. Cutaneous mucormycosis or soft
tissue infections have been linked to the use of contaminated
bandages, needles or wooden tongue depressors in the clinical
setting [47,48]. Also, infections have been acquired by insect
and spider bites or surgical interventions. Importantly, cuta-
neous mucormycosis has been found in otherwise healthy
humans [49–53].
Some cases have been reported where patients suffered
from cutaneous mucormycosis who survived natural disaster
such as tornadoes, hurricanes, tsunamis or volcanic eruptions,
adding the occurrence of ‘natural disasters’ to the list of
putative risk factors for mucormycosis [18,54–56].
Another predisposing factor of mucormycosis is the use of
voriconazole in high risk patients, either for prophylaxis or
treatment of other fungal infections. Voriconazole has been
shown to be inactive against Mucorales in vitro. Mostly, patients
who underwent hematopoetic stem cell transplantation were
at risk for so called breakthrough infections under voriconaz-
ole therapy [57–59]. A surveillance study comparing patients
with mucormycosis to patients with invasive aspergillosis (IA),
showed that many risk factors for these different fungal
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infections were overlapping. However, two risk factors
seemed to be more speciﬁc for mucormycosis than for IA.
One of which was the occurrence of mucormycosis as a
breakthrough infection in patients who were given voriconaz-
ole as prophylaxis [17].
Neonatal prematurity or malnourishment are risk factors
associated mainly with gastrointestinal mucormycosis [60].
Virulence Traits
To understand mucormycosis in more detail, it is of impor-
tance to obtain detailed knowledge about putative virulence
traits of the causing agents, as well as to understand their
interaction with the host immune system. For other fungal
pathogens such as A. fumigatus some potential virulence
factors have been discussed, but not many studies have been
carried out on the members of the Mucoromycotina.
The small conidial size of A. fumigatus is often regarded as a
putative virulence factor because the size allows conidia to
enter the host via respiration. Spore size of the Mucoro-
mycotina is variable, depending on the species 3–11 lm, but in
general bigger than those of A. fumigatus for example. Still, they
can be inhaled and cause disease in the human lungs.
Obviously, the clinically relevant species of the Mucoromy-
cotina are thermotolerant and therefore able to grow at 37°C,
some even at higher temperatures. Nevertheless, in a recent
article by Schwartze et al. [61] the growth speed of clinically
relevant Lichtheimia spp. strains was compared to Lichtheimia
species of which no human cases where reported so far. In
part, slower growth at 37°C of some Lichtheimia species, such
as L. hyalopsora, might explain low virulence potential of these
strains, while for other slow growing Mucorales where shown
to be fully virulent. Therefore, no clear correlation between
growth speed at host temperature and differences in virulence
potential was detected.
On the secretion of proteases, which might contribute to an
easier invasion of host tissue and increase host damage, not
much is know yet, except that some representatives of the
Mucoromycotina have a lot more genes encoding for lytic
enzymes than other fungal pathogens [39,62,63].
Another virulence factor is iron acquisition [44], as iron is
an essential element for fungal cell growth and development.
This was shown to play a major role in virulence of
A. fumigatus [64]. Low iron concentrations in the host
environment, achieved by bound iron to proteins, such as
transferrin, ferritin and lactoferrin, is an effective defence
strategy against invading microorganisms. This strategy seems
to be highly effective against Mucorales, as they were shown to
be extremely restricted in growth in normal serum unless
exogenous iron is added [37,65]. Some pathogens are able to
overcome this limitation by special iron uptake systems. In the
case of A. fumigatus these are reductive iron assimilation or the
production and secretion of siderophores [64]. Contrary to
A. fumigatus, R. oryzae lacks genes for non ribosomal peptides,
the enzymes that produce hydroxamate siderophores, the
most common group of fungal siderophores [62]. It therefore
fully depends on rhizoferrin, which is less efﬁcient, reductive
iron assimilation by rFTR1 and possibly iron acquisition
through degradation of heme by heme oxygenase. Sequence
analysis of the Rhizopus-genome revealed two putative genes
encoding heme oxygenases in Rhizopus [39,66]. The fact, that
the expression of high afﬁnity iron permease rFTR1 is required
for full virulence of Rhizopus in a DKA mouse model,
additionally underlines the correlation of iron uptake and
virulence [44,66]. Nevertheless, iron homeostasis is not fully
characterized in any of the Mucorales yet. Clinically, the link
between iron metabolism in both fungus and host is of high
relevance, because iron overload per se is one major risk factor
in mucormycosis as described in the paragraph on risk factors
for mucormycosis [63,67].
One hallmark of mucormycosis is angioinvasion, and the
ability of a fungal pathogen to invade host cells is a putative
virulence factor. Recently, the glucose regulated protein 78
(GRP78) has been identiﬁed to enable invasion of the pathogen
via an endocytotic mechanism. This endothelial cell receptor
exclusively interacts with Mucorales and not other fungal
pathogens such as A. fumigatus or C. albicans [68,69]. While
GRP78 was shown to be necessary for invasion of endothelial
cells, a receptor involved in-or the mechanism of-adhesion to
endothelial cells was not determined so far [69]. These ﬁndings
were successfully linked to DKA by showing that iron
availability and high glucose levels affect the receptor function.
In contrast, chelating iron with phenanthroline prevented
endothelial invasion and subsequently host cell damage.
Additionally, high iron and glucose levels, as they occur in
DKA patients, induce expression of GRP78 both in vitro and in
DKA mice [69].
Another aspect contributing to virulence of a pathogen is its
capability to evade recognition and elimination by the host
immune system. Phagocytosis of spores was shown to be less
efﬁcient in comparison with conidia of A. fumigatus, which
might partly be attributed to their size and is, similar to damage
and killing by phagocytes, species dependent [70]. Whether
reduced killing of this group of pathogens is due to differences
in recognition patterns is not fully understood yet. Neverthe-
less, a difference in PAMP (pathogen associated molecular
patterns) recognition between R. oryzae and A. fumigatus has
been shown. Whereas recognition of A. fumigatus is mediated
by toll-like receptor 2 (TLR 2) and TLR 4, only TLR 2 seems to
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be involved in recognition of R. oryzae [71,72]. This discrep-
ancy might be attributed to differences in cell wall composition
between Aspergilli and the Mucorales. This needs to be further
investigated, because cell wall composition is not fully
deciphered for all pathogenic Mucorales yet [62,73]. Also,
variations in cytokine release in response to members of the
Mucorales compared to Aspergillus have been detected.
Rhizopus, for example, causes a more pronounced proinﬂam-
matory response with elevated IL-6 release and TNF-a
secretion [74,75]. In general, differential regulation of genes
involved in immune response to R. oryzae was shown to be
less pronounced than in response to A. fumigatus conidia, that
induced a fourfold greater number of differentially expressed
genes in human monocytes [36,73,76].
Concluding Remarks
The key points of mucormycosis, such as the rapid growth of
the various pathogens causing disease, their high afﬁnity to
blood vessels, plus the unique susceptibility of DKA patients to
this disease have long been known, but the molecular
mechanisms involved are still partly deciphered so far. The
identiﬁcation of one receptor (GRP78) and its necessity for
virulence and regulation by both iron and hyperglycaemia has
been a break-through in mucormycosis research. Hopefully, in
the next years additional members of the Mucorales will have
their genomes sequenced and annotated, which will help to
decipher virulence traits and to better understand the
host-pathogen interaction.
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